Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
Cell and Gene Therapy Today—July 2, 2026
This week’s Gene and Cell Therapy update highlights regulatory progress,…
Rare Diseases Today—July 2, 2026
This week’s Rare Diseases update highlights regulatory decisions, late-stage…
Cell and Gene Therapy Today—June 18, 2026
This week’s Gene and Cell Therapy update highlights early clinical progress,…
Neuroscience Today—June 17, 2026
This week’s Neuroscience update highlights regulatory decisions, late-stage…
Rare Diseases Today—June 11, 2026
This week’s Rare Diseases update highlights regulatory approvals, pediatric…
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Cell and Gene Therapy Today—May 21, 2026
This week’s Gene and Cell Therapy update highlights regulatory progress,…
Rare Diseases Today—April 30, 2026
This week’s Rare Diseases update highlights regulatory actions, clinical…
Cell and Gene Therapy Today—April 23, 2026
This week’s Gene and Cell Therapy update highlights regulatory momentum,…
Rare Diseases Today—March 26, 2026
This week’s Rare Diseases update highlights regulatory designations, new…